Dacomitinib is a targeted therapeutic drug for non-small cell lung cancer (NSCLC) with positive EGFR mutations. As a second-generation irreversible EGFR tyrosine kinase inhibitor, it demonstrates significant advantages in prolonging patients' progression-free survival. Dacomitinib has been launched in China and included in China's national medical insurance scheme. The original research drug is available in a specification of 45mg*30 capsules, with a price of approximately 858 US dollars per box.
How to Purchase Authentic Dacomitinib
Dacomitinib has been launched in China and covered by medical insurance, allowing patients to buy it through multiple formal channels. Understanding these purchase channels helps ensure access to high-quality medications.
Purchase from Hospital Pharmacies
Oncology-specialized pharmacies in domestic hospitals are usually stocked with Dacomitinib. Patients can purchase it directly with a doctor's prescription. The original research drug by Pfizer comes in a specification of 45mg*30 capsules, priced at approximately 858 US dollars per box. The above price is for reference only.
Purchase from Formal Chain Pharmacies
Large-scale chain pharmacies can provide Dacomitinib. When purchasing, patients are required to present a valid prescription, and pharmacists will offer professional medication guidance.
Online Pharmaceutical Platforms
Platforms with Internet hospital qualifications support online medical consultation and drug delivery. It is necessary to confirm that the platform holds valid drug operation qualifications. Purchasing through formal channels and verifying the drug approval number and production batch number are important prerequisites for medication safety.
Usage and Dosage of Dacomitinib
Correct use of Dacomitinib is beneficial for exerting its therapeutic effect and reducing adverse reactions. The following are key medication guidelines.
Standard Administration Regimen
The recommended dose is 45mg taken orally once a day, which can be administered with food or on an empty stomach. The drug must be taken at a fixed time every day. If a dose is missed, there is no need to make up for it; instead, take the next scheduled dose as planned.
Dosage Adjustment for Special Populations
Patients with mild to moderate hepatic or renal impairment do not require dosage adjustment.
Patients with severe renal impairment (CLcr < 30mL/min) should use the drug with caution.
Elderly patients need close monitoring for adverse reactions.
Contraindications for Combined Medication
Concurrent use with proton pump inhibitors should be avoided.
If antacids are necessary, it is recommended to use locally acting preparations or H2 receptor antagonists, with an interval of more than 6 hours between administrations.
Strictly following the doctor's advice and conducting regular follow-up examinations can help Dacomitinib achieve the optimal therapeutic effect.
Therapeutic Effect of Dacomitinib
Dacomitinib has shown significant clinical efficacy in patients with EGFR mutation-positive NSCLC, providing a new treatment option for such patients.
Progression-Free Survival (PFS)
Clinical studies have shown that the median progression-free survival of patients with EGFR mutations receiving first-line treatment with Dacomitinib is significantly longer than that of those treated with first-generation TKIs.
Objective Response Rate (ORR)
In registered clinical trials, Dacomitinib achieved a high objective response rate and a high disease control rate, with significant tumor shrinkage observed in most patients.
Long-Term Survival Benefit
The ARCHER 1050 study showed that the median overall survival of patients in the Dacomitinib group was longer than that in the control group.
Standardized use of Dacomitinib can significantly prolong patients' survival time and improve their quality of life, making it an important treatment option for patients with EGFR mutations.
